You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Results from base-case analyses

From: Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany

a: Overall effects [cohort of 1 million individuals not discounted]
  Number of HZ-cases Costs of treatment (€) Costs of vaccination (€) Total costs (€) BCR*
Status quo 284,768 127,978,000 - 127,978,000  
Vaccination scenario 264,977 117,948,913 29,496,000 147,444,913 0.34
b: Number needed to vaccinate (NNV)
Avoiding one HZ-case   10    
Avoiding one PHN-case   144    
Gaining one QALY   195    
c: Costs and effects in both scenarios of the model
Not discounted Costs (€) Effects [QALY] Costs/Effects ICER
Status quo   127.98 29.2747 4.3716  
Vaccination scenario   147.44 29.2757 5.0364 19,002
Discounted     
Status quo   82.80 18.8569 4.3911  
Vaccination scenario   98.64 18.8574 5.2307 28,146
  1. *Benefit-Cost ratio; , Euro in 2010 price levels.ICER, incremental cost-effectiveness ratio; HZ, herpes zoster; PHN, postherpetic neuralgia; QALY, quality adjusted life-year.